Examkin

Soru

Zorluk: Çok zorHematology and Oncology

A 65-year-old woman is hospitalized for a deep vein thrombosis and treated with an unfractionated heparin infusion. On day 66 of hospitalization, her platelet count falls from 240,000/mm3240,000/\text{mm}^3 on admission to 75,000/mm375,000/\text{mm}^3. Physical examination reveals a new, painful, swollen, and pulseless right foot. Her 4T score is calculated to be 77, indicating a high probability of heparin-induced thrombocytopenia (HIT) complicated by arterial thrombosis. Arrange the following management steps in the correct chronological sequence for this patient.

  1. 1Discontinue all current heparin-containing products
  2. 2Initiate a non-heparin intravenous anticoagulant (e.g., argatroban)
  3. 3Confirm platelet count recovery to ≥150,000/mm3\geq 150,000/\text{mm}^3
  4. 4Initiate oral warfarin therapy
  5. 5Overlap the non-heparin anticoagulant and warfarin until the INR is therapeutic for 4848 hours

Cevap

The correct sequence is to first discontinue all heparin, immediately initiate a non-heparin anticoagulant like argatroban, wait for platelet count recovery to at least 150,000/mm3150,000/\text{mm}^3, then initiate warfarin, and finally overlap both agents until the INR is therapeutic.
The clinical management of Heparin-Induced Thrombocytopenia (HIT) relies on a rigid chronological sequence. Upon suspecting HIT (e.g., a high 4T score), all heparin must be discontinued to stop the immune trigger. Because patients remain at extremely high risk for thrombosis, an alternative anticoagulant (e.g., argatroban, bivalirudin) must be started immediately. The timing of the transition to oral warfarin is heavily tested: warfarin must NEVER be started until the platelet count has recovered to ≥150,000/mm3\geq 150,000/\text{mm}^3. Starting warfarin earlier causes a rapid decline in Protein C (a natural anticoagulant with a short half-life), worsening the hypercoagulable state and risking venous limb gangrene. Once platelets recover, warfarin is started, and the two anticoagulants must be overlapped until the INR is therapeutic for 4848 hours.

Adım Adım Çözüm

1
Recognize high-probability HIT and immediately stop all heparin exposure.
Halts the formation of new PF4-heparin immune complexes.
Continuing heparin fuels the underlying pathophysiology of platelet activation and thrombosis.
2
Start an alternative anticoagulant such as a direct thrombin inhibitor (argatroban).
Provides immediate therapeutic anticoagulation.
HIT is extremely prothrombotic; stopping heparin alone is insufficient to prevent severe thrombotic complications like limb loss.
3
Monitor platelet counts daily until they reach ≥150,000/mm3\geq 150,000/\text{mm}^3.
Identifies the resolution of the acute thrombocytopenic phase.
Transitioning to oral vitamin K antagonists during acute thrombocytopenia is strictly contraindicated.
4
Start oral warfarin therapy only after platelet recovery is confirmed.
Begins long-term oral anticoagulation.
Early warfarin use causes rapid depletion of Protein C, which can lead to catastrophic venous limb gangrene.
5
Continue the direct thrombin inhibitor alongside warfarin for at least 55 days and until the INR is ≥2.0\geq 2.0 for 4848 hours.
Ensures continuous anticoagulant coverage during the transition.
Warfarin creates a transient hypercoagulable state during the first few days of therapy due to differing half-lives of vitamin K-dependent factors.

Anahtar Kavram

Management algorithm and therapeutic sequencing for Heparin-Induced Thrombocytopenia (HIT)
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru